Table 2.

Prediction of MP Intolerance by TPMT and NUDT15 Genetic Variants

MP Dose Intensity, %*	Genetic Risk Score†
	< 2	≥ 2
≤ 50	50	7
> 50	599	0

NOTE. Genotype and MP dose intensity based on AALL03N1 cohort.

Abbreviation: MP, mercaptopurine.

^*Overall MP dose intensity was summarized for entire 6-month study period.

^†Genetic risk score was defined by number of TPMT and/or NUDT15 risk alleles (rs1142345, rs1800462, rs1800460, and rs116855232), as described in Patients and Methods.